Cala Health is a private bioelectronic medicine company developing noninvasive, wearable neuromodulation therapies for chronic neurological conditions, and this article summarizes its key developments over the past week. The company focuses on its Cala kIQ System and Transcutaneous Afferent Patterned Stimulation, or TAPS, therapy to address essential tremor and Parkinson’s-related hand tremors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
During the week, Cala Health received industry recognition as a winner in the 2026 MedTech Breakthrough Awards in the Medical Device: Best New Technology Solution – Neurology category. The award specifically highlighted the company’s Cala kIQ wearable neuromodulation platform and its TAPS Therapy, which is designed to provide temporary relief of hand tremors in adults with essential tremor.
The Cala kIQ device is currently described as the only FDA-cleared wearable delivering effective therapy for action hand tremor in both essential tremor and Parkinson’s disease. This external validation from a specialized medtech awards program reinforces Cala Health’s positioning in the growing neuromodulation and digital durable medical equipment market.
The recognition may bolster the company’s visibility among clinicians, payers, and patients as it seeks to expand access and scale its direct-to-home delivery model. While the award itself does not directly translate into financial results, it can support commercialization efforts, reimbursement discussions, and potential strategic partnerships.
In parallel, Cala Health increased its scientific and clinical profile by participating in the 3rd International Tremor Congress in Tampa. Founder Kate Rosenbluth, Ph.D., and clinical collaborators presented updates on clinical evidence for wearable neuromodulation in TAPS therapy to an audience of movement disorder specialists and neurologists.
Presentations at the congress included data on how noninvasive TAPS may treat refractory essential tremor, with references to electrophysiologic evidence of ventral intermediate nucleus, or VIM, modulation and PET-based network effects. By contributing to peer-reviewed discourse and emphasizing data-driven evidence, the company aims to support deeper clinician adoption of its technology.
These scientific activities may help establish TAPS as a credible option within mainstream tremor treatment algorithms and differentiate Cala Health’s approach from other neuromodulation offerings. Over time, robust clinical data and academic engagement could aid in securing broader reimbursement and driving more widespread clinical use.
Overall, the week marked a combination of reputational and scientific milestones for Cala Health, with industry awards and congress presentations both underscoring momentum behind its wearable neuromodulation platform. These developments strengthen the company’s positioning as it competes in a crowded neuromodulation market and prepares for broader commercial scaling.